Dear Friends,

The Hepatitis B Foundation (HBF) and the Baruch S. Blumberg Institute, which we established to fulfill our research mission, are both in very strong positions as we look to the future.

Next year HBF will celebrate its 25th Anniversary, so it is only fitting that our new strategic plan includes the ambitious goal that no one will die from hepatitis B by 2030. Although audacious, it is in alignment with the World Health Organization’s global hepatitis plan that calls for the elimination of hepatitis B and C by 2030.

This will require national and international action, which the HBF is already helping to lead.

The HBF’s international programs have become models of hepatitis B outreach. In Ho Chi Minh City, Vietnam we are partners in a project to reach 10,000 at-risk individuals with screening and linkage to care efforts. This effort builds on our ongoing Haimen City, China program, which has now reached more than 1 million individuals and brought almost 2,000 patients into care.

In the U.S., we continue to lead national advocacy efforts with Capitol Hill visits; ensure that hepatitis B and liver cancer are included in appropriation language; and host Congressional briefings on hepatitis B issues.

At the Blumberg Institute, our drug discovery program is working at full speed, powered by the successful $3 million Nobel Challenge campaign that enabled us to recruit 5 renowned scientists in the field! But it is our research collaboration with Arbutus Biopharma that will truly make a difference in rapidly advancing our discoveries from the lab to the clinic.

Within the next year, it is entirely conceivable that the drugs we discovered, or helped to discover, will start being tested in people. That speed of progress is almost unprecedented in drug discovery.

The HBF and the Blumberg Institute are very strong. But we can’t be complacent. Our new strategic plan will lead us to transformational discoveries and provide a strong basis for our continued ability to provide vision and leadership in making hepatitis B history.

Joel Rosen, Esq.
Chairman of the Board

Timothy M. Block, PhD
President and Co-Founder

The Hepatitis B Foundation is a national nonprofit organization dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide through research, education and patient advocacy.
Driving Research

The Baruch S. Blumberg Institute, established by the Hepatitis B Foundation to fulfill its research mission, is closing in on its search to find a cure for hepatitis B. With nearly 50 scientists, the Blumberg Institute may now be the largest group of nonprofit researchers working on hepatitis B in the world.

This year the HBF met A Nobel Challenge and raised $3 million to help the Blumberg Institute recruit top scientific talent to accelerate the pace of research. Our goal, however, is not merely to support the development of new hepatitis B treatments or to raise awareness about this serious liver disease. Our mission is to eliminate hepatitis B, to relegate it to the history books. The extraordinarily successful Nobel Challenge campaign is powering our efforts to do precisely that.

The Blumberg Institute recruited 5 renowned scientists to work full time on hepatitis B research as a result of the HBF’s successful $3 million fundraising campaign. Standing L to R: **Drs. Tianlun Zhou, Jinhong Chang, Ying-Hsiu Su, Timothy Block, and Ju-Tao Guo.** (March 2015)

Our Breakthroughs

The Blumberg Institute and its world-class researchers are significantly driving the scientific momentum towards innovative ways to combat the hepatitis B virus (HBV). Today, we are committing everything we have, every resource at our disposal, in pursuit of a cure to benefit the more than 240 million people living with hepatitis B worldwide.

**Novel HBV Therapeutic Targets**

**cccDNA Inhibitors Fast Tracked**

We are among the first, if not the only, to identify a small molecule inhibitor of HBV cccDNA formation, which is very significant since inhibition of cccDNA is considered essential in achieving a complete cure. The drug has now been made highly active and is licensed for further development to Arbutus Biopharma, the first company solely dedicated to HBV drug discovery (read more on page 4).

**Designer Drugs**

**Drs. John Kulp and Yanming Du** are using computer modeling to design and produce targeted HBV and liver cancer drugs that include new HBV capsid inhibitors and “YES kinase” inhibitors.

**Harnessing the Immune System**

**Drs. Ju-Tao Guo and Jinhong Chang** have developed a new HBV drug that works by activating an infected liver cell’s own immune defenses, which has shown to be effective in animal studies.

**HBV Drugs, Naturally**

**Drs. Tianlun Zhou and John Kulp** have screened thousands of plant and fungal extracts from our extensive Natural Products Collection, donated to us by Merck & Co. in 2011, to mine for drugs derived from “natural products” that inhibit HBV cccDNA and viral proteins. The exciting news is that their work has resulted in two new leads that show activity against HBV.
Detecting Liver Cancer Early

A blinded study using DNA markers developed by Dr. Ying-Hsiu Su in collaboration with researchers at Thomas Jefferson University were found to detect liver cancer more effectively than currently approved methods. The study results showed that Dr. Su’s markers were superior to alpha-feto protein (AFP) in detecting liver cancer in people. Indeed, her urine-based assay detected at least 90% of primary liver cancer at early stages.

A Better Formula for Predicting Cancer

The Doylestown Algorithm, developed by Blumberg Institute and Drexel University scientists, is ready to take center stage! No new tests are required for this formula to be used, just the tests a doctor already orders. In a study with more than 2,000 people, the Doylestown Algorithm was found to be a better predictor of liver cancer than current blood test markers alone.

In 2015...

New Blumberg Institute Partnership with Arbutus Biopharma

In 2015, the Blumberg Institute entered into a three-year research agreement with Arbutus Biopharma, a company focused solely on HBV drug development. This unique partnership will allow us to move our discoveries more rapidly from proof-of-principle stage — through translational research — into human clinical trials. Our scientists will work collaboratively with Arbutus on novel approaches to HBV and liver cancer, based on an overarching research plan with the shared goal of developing a cure for hepatitis B, which causes up to 1 million deaths each year worldwide. (April 2015)
International HBV Meeting Goes Viral

The International HBV Meeting, coordinated by the Hepatitis B Foundation and the annual definitive meeting on the molecular biology of hepatitis B and D, is truly going viral as interest in HBV as a curable disease gains momentum. The 2015 HBV Meeting was held in October with more than 400 scientists from around the world traveling to Bad Nauheim, Germany. Co-chairs Drs. Haitao Guo (Indiana U, USA) and Dieter Glebe (Giessen U, Germany) kicked off the meeting with a clinical symposium that brought HBV molecular biologists together with physicians and drug development professionals to stimulate collaborations and accelerate the pace of drug discovery research for hepatitis B.

2015 Bruce Witte Lecturer: Dr. Hashem El-Serag

Each year HBF invites an outstanding leader in the field to give the Bruce Witte Distinguished Lecture and Hashem El-Serag, MD, MPH (right) was invited to present his important research on hepatitis B and liver cancer. This named lectureship is generously sponsored by HBF co-founders Paul and Janine Witte. (March 19, 2015)

3 Student Winners at the 2015 Siemens Competition

The HBF Summer Research Internship Program is advancing the national STEM priorities by providing college and high school students with valuable “hands-on” experience in the Blumberg Institute labs under the supervision of professional scientists. Since the year 2000, we have graduated 126 alumni who have gone on to college, graduate or medical school, and employment in biotech or pharmaceutical companies. This summer 3 of our high school interns in Dr. Ying-Hsiu Su’s lab won team honors for their research project at the Siemens Competition. (L to R: HBF Summer High School Student Interns Gerald Liu, Emily Cheng, and Kelly Jiang at the Siemens Competition in Math, Science and Technology held at George Washington University. Photo provided by Emily Cheng).

Our Liver Cancer Recommendations Published by Journal of the National Cancer Institute

A group of 20 of the nation’s leading liver cancer experts were convened for the HBF’s bi-annual Princeton Workshop in March 2015 to focus on improving screening and care for those with HBV-related liver cancer. Over two days, the group discussed the gaps and limitations in current approaches for the detection and treatment of primary liver cancer, and defined research priorities and opportunities for advocacy. A summary of the liver cancer recommendations has been published in the Journal of the National Cancer Institute, which is available online and will appear in the April 2016 print issue.
Impacting Public Health

Elimination of hepatitis B is the ultimate goal of the Hepatitis B Foundation and the focus of our public health programs. To achieve this goal, we have developed successful community-based programs to increase vaccination, screening and linkage to care to stop the spread of this deadly virus.

To harness the community energy and maintain the momentum, we are building coalitions at the local, national and international levels to improve capacity to ensure that every person knows their hepatitis B status and has access to the care they need to prevent a new infection or treat a chronic infection.

OUR LOCAL IMPACT

In 2008 the HBF created a program to address hepatitis B in its own backyard – Philadelphia! Over the past 7 years this program has grown into a thriving hepatitis B coalition of 75 members that work together in high-risk communities to educate, screen and link individuals to care. It has also become a model to test promising best practices to improve efficiency and health outcomes around hepatitis B nationwide. In 2012, the coalition was renamed Hep B United Philadelphia.

Led by HBF leaders and the Hep B United Philadelphia coalition, more than 60 advocates stormed City Hall to demand an end to the silence around viral hepatitis. (May 2015)

OUR NATIONAL IMPACT

HBF, in partnership with AAPCHO (Association of Asian Pacific Community Health Organizations), created and leads Hep B United, a national coalition of 24 member coalitions across the country that are working to address hepatitis B in their local communities. Hep B United members are finding success in bringing together key stakeholders such as community-based organizations, healthcare providers, hospitals and clinics, state and local health departments, student groups, and elected officials and community leaders to increase HBV awareness, screening, vaccination and linkage to care in high-risk communities.

Hep B United is also proud to be an official partner of the Centers for Disease Control and Prevention and is co-branded with its Know Hepatitis B campaign, their first national multi-lingual awareness campaign on hepatitis B.

The Hep B United 3rd National Summit in Washington, DC also included visits to members of Congress on World Hepatitis Day. Advocates stand with Congressman Mike Honda from California (center) who is our key HBV champion! (July 28, 2015)
OUR INTERNATIONAL IMPACT

Since 2011 the HBF has conducted an ambitious public health HBV program in Haimen City, China to reach all 1 million residents. The citywide campaign included educating physicians, government officials, community leaders, the general public, and testing all pregnant women over a 12-month period.

Today we are focused on strategies to empower patients to take control of their own care and to partner with their providers to improve their long-term health.

As we look to the future, we plan to build on our success and use Haimen City as a model for other high-prevalence countries, which currently includes supporting a program in Vietnam and sharing our experiences with leaders in Mongolia.

Hepatitis B Foundation in Haimen City, China

1 million (100%) residents educated

1,441 (90%) healthcare providers trained

5,407 (100%) pregnant women screened over one-year period

12,000 people screened for hepatitis B

1,382 enrolled in patient empowerment program

“I am so grateful for the advice given. You have given me so much hope and reason to live again.”

“You have restored a lot of strength and hope in me.”
Living Outreach

The Hepatitis B Foundation is a beacon of hope for the more than 240 million people worldwide who live with hepatitis B. We provide valuable information and support through our Help Lines via phone, email and social media. Our counselors answer questions about test results, transmission, vaccination, and treatment. We link people to care by referring them to healthcare providers, clinical trials and other resources in the U.S. and abroad.

Connections for the Liver Cancer Journey

Our web-based LiverCancerConnect.org program provides people diagnosed with primary liver cancer accurate information and timely referrals to expert medical care.

With liver cancer rates exploding — it is now the 2nd most common cause of death from cancer worldwide, with HBV being the primary cause of liver cancer — there is a tremendous need for patient-focused information.

In the United States, liver cancer is one of the only cancers that is increasing in incidence while most cancer rates are decreasing.

Behind all of these staggering facts, however, are patients and families struggling with liver cancer, which is why we created LiverCancerConnect.org. Our goal is to connect people with the information, support and resources they need to bring hope to their liver cancer journey.
Hepatitis B is the most common, serious liver disease in the world and it thrives on silence. To bring hepatitis B out of the shadows, the Hepatitis B Foundation is leading the effort to turn up the volume to prioritize hepatitis B as an urgent health priority. As the foremost research and disease advocacy organization for hepatitis B, we are speaking out on the national and international stage to demand increased attention and funding to eliminate hepatitis B once and for all.

1st World Hepatitis Summit Held in Scotland

The World Health Organization (WHO), in joint partnership with the Scottish Government and the World Hepatitis Alliance, co-organized the 1st World Hepatitis Summit in Glasgow, Scotland on September 2-4, 2015.

More than 80 countries were represented with 600 leaders from government, public health agencies, and non-governmental organizations participating.

The HBF presented about its successes and challenges in the U.S. during a pre-summit conference. The message was serious. Hepatitis B and C kill more people each year than HIV/AIDS and tuberculosis combined, and represent the 7th leading cause of death worldwide, yet viral hepatitis as a global health concern remains mostly invisible and under-funded.

Without significant intervention, WHO estimates there will be 20 million needless deaths over the next 15 years around the world. WHO leaders unveiled their draft global viral hepatitis plan, the first of its kind. Its twin goals of reducing chronic viral hepatitis cases by 90 percent and deaths by 65 percent by 2030 are ambitious, but possible.

CAPITOL HIGHLIGHTS

- HBF helped organize the first joint Hepatitis on the Hill visits to members of Congress in March that brought more than 100 hepatitis advocates to Washington, DC. Patients and family members shared their stories to put a human face on the devastating impact of viral hepatitis and to call for increased federal funding to address the viral hepatitis epidemic.

- On July 28, designated World Hepatitis Day by the World Health Organization in honor of Dr. Baruch Blumberg’s birthday, a commemorative White House Briefing honored national leaders, including Joan Block, HBF executive director and co-founder, for advancing the goals of the U.S. National Viral Hepatitis Action Plan.

- The National Academy of Medicine (formerly the Institute of Medicine or IOM) invited Dr. Robert Gish, HBF medical director, and Dr. Chari Cohen, HBF director of Public Health, to share expert testimony as the Academy prepares its report on the elimination of viral hepatitis in the United States, slated for release in 2016.
Our 18-Month Donor Honor Roll

JULY 1, 2014 - DECEMBER 31, 2015

Funding Our Vision

The Hepatitis B Foundation’s valuable research and patient programs are made possible by the commitment of our donors. We are grateful to everyone who has generously supported our mission through individual gifts, grants, matching gift programs, in-kind donations, and sponsorships and attendance at our special events. Thank you!

Benefactors Society

Visionary Circle ($10,000 and more)
- Timothy & Joan Block
- Bruce & Cyndie Maryanoff
- The John J. McDonnell Margaret T. O’Brien Foundation

Global Circle ($5,000 to $9,999)
- Anonymous
- Catharine & Robert Williams
- Marvin & Dee Ann Woodall

Founders Circle ($2,500 to $4,999)
- Anonymous
- Bonnie Chang & Robert Hsu
- Anthony & Jane Ford-Hutchinson
- High Swartz LLP
- Per Karlsson
- Joel D. Rosen

Presidents Club ($1,000- $2,499)
- Anonymous
- APA Medical Student Association
- Benevity Community Impact Fund
- Stan & Gerri Broadbent
- Ronald Chang
- Gang Chen
- Dr. & Mrs. Moon Chen
- Cross Current Corporation
- Loren & Jennie Danzis
- Beatriz De Oliveira Costa & Eric Stollnitz
- EisnerAmper LLP
- Craig & Janet Esterly
- Fox Rothschild LLP
- Curt & Rosanne Friehs
- Gilmore & Associates
- Joseph Hediger
- Chunbao Paul Hsu
- Joanne Jensen & Lewis C. Wakefield
- Richmond Jin
- Terry Kaplan
- Robert Kelley
- Amy Ko-Tang
- Faye & Mayer Krupp Family Charitable Foundation
- W. Thomas & Linda London
- Mary Anne McDonald & Joe Benning
- Anand & Valerie Mehta
- Jean C. Miller
- Debora Nelson
- Pamela Norton & Joseph Pottz
- The Norwood Company
- Madhu Parakala
- Penn Color
- PMV Pharma
- Protient LLC
- Yusheng Qu
- Jonathan & Virginia Shames
- Thomas Shenk & Lillian Chiang
- S.R. Wojdak & Associates
- Thomas Stellini
- Yee Yan Tan
- Bud & Priscilla Tennant
- Teera Tosukhowong
- Walter Tsou
- Paul & Janine Witte
- Worth & Company, Inc.
- Bing Xue & Xiaoshun Yu
- Wayne F. Yeter

Patrons ($500 to $999)
- Anonymous
- AASLD
- Apple, Inc.
- Victor & Theresa Araya
- Dr. & Mrs. Clement Au
- Bartlett & Company, Inc.
- Eileen Beck
- Carol Brosgart
- Alan & Patty Brownstein
- Mr. & Mrs. Richard A. Celender
- Stephen & Maureen Chadwick
- Mr. & Mrs. Andrew Chen
- Michael Christenson
- Steven & Janet Cohen
- CP Commercial Printing
- CSD Engineers
- Demusz Brothers, Inc.
- Diversified Refrigeration, Inc.
- D. Rodman & Valerie Eastburn
- Flowmetric, Inc.
- Daniel & Jamie Fox
- Robert B. Frey
- Genesis Biotechnology Group
- The Graphic Edge
- Carol & Franklin Hart
- Joyce Huber & Randall Ellis
- IBM Employee Services Center
- IteraMed
- Margaret Keenan
- Seung Hee Kim
- Richard Koch
- Kevin Kruse
- William Kwok & Catherine Ng
- Anna Lee
- Jennifer Maher
- Makindus, Inc.
- Samuel P. Mandell Foundation
- Daniel McGinn
- James & Barbara Mongold
- Janice L. Morris
- Loujan Mourad
- Douglas Roessler
- Giuseppe Sarrica
- Softerware Inc.
- Spark Nonprofit Consulting
- Tescor Inc.
- Su Wang
- Michael D. Wehner
- Dennis & Ailee Wen
- Paul & Ellyn Wilkinson
- Worldwide Life Sciences Division

Fellows ($250 to $499)
- Anonymous
- Mr. & Mrs. Joseph Aceto
- Advanced Vertebral Solutions
- Amazon Smile Foundation
- Artemis Solutions, Inc.
- Bee Bergvall & Co.
- BKG Company, Inc.
- Gregory & Susan Braithwaite
- Bucks County Community College
- Faith Calhoun
- Caring Ambassadors Program
- Cong Cheng
- Joe & Molli Conti
- David Charles Crane
- Del Val Power & Light, Inc.
- Betty Dodson
- Joshua Feldstein
- Mr. & Mrs. Theodore Feldstein
- Fox Chase Chemical Diversity Center
- Alan & Ima Freedman
- Joseph Gonnella
- David & Cynthia Gruber
- Khin M. Gyi
- Bill & Sue Hermann Family Fund of the Community Foundation for Southeast Michigan
- Mr. & Mrs. Peter E. Hoekstra
- InterLink Biotechnologies
- JBS Science, Inc.
- Bonnie & Robert Jung
- Ufuk Karaaslan
- Kistler-Tiffany Benefits
- Anh Tuyet Le
- Raymond Lee & Julia Liu
- Lone Oak Medical Technologies
- John J. Lynch
- Scott & Daryl MacKeeverican
- Mr. & Mrs. Michael Milewski
- Jennifer Minarcik
- Moyer Indoor Outdoor
- North American Benefits Company
- Phanendrakumar Pennmetsa
- Pharmabridge Inc.
- Richard & Priscilla Rosenberger
- Caroline Satchell
- Schiff Center for Liver Diseases
- Shady Maple Farm Market
- Kunwar Shahlabhia
- Y. Clement Shek
- Ronald Sicilia
- Mike & Suzanne Stapleton
- William & Irene Taylor
- Trovib Biosciences, LLC
- C. Theodore Tucker
- Vickery Vaccine Services
- Sharon Victor & Abraham Leibson
It’s an exciting time for a cure is within reach.

Joan C. Copp
Margaret Copeland
Chari & Paul Cohen
David & Kathleen Christenson
Jinhong Chang
Garrett Chang
Joseph & Amy Chan
Everett & Diana Chambers
Mr. & Mrs. William E. Cayley
Michael C. Carr
Pamela Cantrell-Self
Nelson Campbell
The Brooks Group & Associates, Inc.
Boat People SOS, Inc.
Anne Blumberg & Jonathan Dorfman
Karen Blu
Geraldine Block
Kathryn Berger
Joanne Blasenheim
Kathryn Berger
Ian & Michele Hooper
Mr. & Mrs. David Hines
Andrew Asa Hindman
David & Kristina Hill
James & Carol Curry
Kim & Chris David
Tacie Dejanikus
The Do Family Living Trust
Son T. Do
Dr. & Mrs. William R. Donaldson
John & Sandy Draus
Yanning Du
Dominik Duelli
Peggy & James Farley
Steven Felles
Thomas L. Freeman
Lawrence Friedman & Mary Jo Cappuccilli
Glenn G. Galang
Roger & Nancy Gallic
Paul & Elizabeth Galvin
David Gaskin
Julie Gerhardt Jacob
Sudhanya Gnaneshwar
Charles & Donna Grezlak
Richard Grillo
Ju-Tao Guo
Renee T. Haliburton
Hie-Won Hann
David C. Harper
Anne M. Heacock
James & Elena Hickey
David & Kristina Hill
Andrew Asa Hindman
Mr. & Mrs. David Hines
Ian & Michele Hooper
Anu Hosangadi
Yuko Hwang
Gary & Kathy Jacob
Jeffrey & Violetta Jacobson
Dr. & Mrs. Barry Kahn
Maureen M. Kamischke
Christie Kan
Nina & Paul Katz
Debra Krupp
Keith Kuenzli
Eric Edward Kvick & Nancy Marie Sidun
Patrick Y. Lam
Michael & Jan Landis
Jonah & Amy Lansky
Karen E. Lassman-Eul
Feng & Meihuei Lee
Janet Lee
Rachel G. Letkowitz
Stephen & Susan Leshnoff
Devon Lewis
Yun Li
King & Ying Liang
Michael Limpe
Mr. & Mrs. Michael D. Line
Yi Liu
Kenneth K. Lu
Jun Luo
Juan & Maria Echieverria Maldacena
Emily Mao
Patti McAlloon
Thomas & Victoria McDowell
Brian McMahon
Mr. & Mrs. Shanti Mehta
Banti Modi
Catherine Morris & Richard Bader
Santosh Nair & Priya Joshi
Network for Good
Mark G. Obergmann
Robert Olanoff
Paulo Oliveira
Val Orekhov
Eleanor Orth
Donald & Jo Page
Linda Park
Steve Pelland
David Provenzano
Brian Quigley
Vivek Ravishanker
Yue Fan Ren
Nicola F. & Carol W. Rico
Charle Rife
Bryce Roberts
Salesforce.Org
James C. Samuels-Davis
Ronald & Joyce Sanderson
Mr. & Mrs. Michel Serieyssol
John & Susan Shelly
Robert & Mary Sheppard
Lucille Sherbondy
Tom & Praneer Sherbondy
Raymond Skerrett
Harriet & Thomas Stenzel
Ephraim & Myriam Sudit
David Suen
Linhlai Sui
David Sul
Dr. & Mrs. James Talamonti
Judy Tam
Terence Tam
Joly Tang & Kristiani Himawan
Leop Thaich
Tuan Tran
William M. Trust, Jr.
Mr. & Mrs. Christian J.A. Urciuoli
Vanguard Cleaning
Voya
Charles E. Wagner
Mr. & Mrs. Ian Walmsley
John J. Walsh & Annie Xu Lloyd
Patrick & Margaret Walsh
Deborah Wexler
Mr. & Mrs. Thomas N. Wight
Harold & Elenore Winkler
Shari Winkler
George P. Wong
Stephen Wong
Onanong Wongwichai
Xenobiotic Laboratories, Inc.
Mai Chong Yang
Yim E. Yeung
Mr. & Mrs. Alan Chung-I Yu
Jeannie Zerdes

“In the twelve years that I have been a member of the foundation’s board of directors, I have never been more optimistic that a cure is within reach. It’s an exciting time for everyone involved.”

— Joel Rosen, HBF Board Chairman

SUPPORTERS (S100 to $249)
Anonymous
Acora Therapeutics, Inc.
Ishola S. Adeyemo
Joann Albert & Daniel Greene
Joseph Amon & Erin E. Galbraith
Fekadu Ashenafi
Joseph & Amy Chan
Susan B. Baker
Sudhantha Bhandari
John Massey
Sandra Bendt
David B. Behner
Kathryn Berger
Joanne Blasenheim
Geraldine Block
Karen Blu
Anne Blumberg & Jonathan Dorfman
Boat People SOS, Inc.
The Brooks Group & Associates, Inc.
Nelson Campbell
Pamela Cantrell-Self
Michael C. Carr
Mr. & Mrs. William E. Cayley
Eric Edward Kvick & Nancy Marie Sidun
Patrick Y. Lam
Michael & Jan Landis
Jonah & Amy Lansky
Karen E. Lassman-Eul
Feng & Meihuei Lee
Janet Lee
Rachel G. Letkowitz
Stephen & Susan Leshnoff
Devon Lewis
Yun Li
King & Ying Liang
Michael Limpe
Mr. & Mrs. Michael D. Line
Yi Liu
Kenneth K. Lu
Jun Luo
Juan & Maria Echieverria Maldacena
Emily Mao
Patti McAlloon
Thomas & Victoria McDowell
Brian McMahon
Mr. & Mrs. Shanti Mehta
Banti Modi
Catherine Morris & Richard Bader
Santosh Nair & Priya Joshi
Network for Good
Mark G. Obergmann
Robert Olanoff
Paulo Oliveira
Val Orekhov
Eleanor Orth
Donald & Jo Page
Linda Park
Steve Pelland
David Provenzano
Brian Quigley
Vivek Ravishanker
Yue Fan Ren
Nicola F. & Carol W. Rico
Charle Rife
Bryce Roberts
Salesforce.Org
James C. Samuels-Davis
Ronald & Joyce Sanderson
Mr. & Mrs. Michel Serieyssol
John & Susan Shelly
Robert & Mary Sheppard
Lucille Sherbondy
Tom & Praneer Sherbondy
Raymond Skerrett
Harriet & Thomas Stenzel
Ephraim & Myriam Sudit
David Suen
Linhlai Sui
David Sul
Dr. & Mrs. James Talamonti
Judy Tam
Terence Tam
Joly Tang & Kristiani Himawan
Leop Thaich
Tuan Tran
William M. Trust, Jr.
Mr. & Mrs. Christian J.A. Urciuoli
Vanguard Cleaning
Voya
Charles E. Wagner
Mr. & Mrs. Ian Walmsley
John J. Walsh & Annie Xu Lloyd
Patrick & Margaret Walsh
Deborah Wexler
Mr. & Mrs. Thomas N. Wight
Harold & Elenore Winkler
Shari Winkler
George P. Wong
Stephen Wong
Onanong Wongwichai
Xenobiotic Laboratories, Inc.
Mai Chong Yang
Yim E. Yeung
Mr. & Mrs. Alan Chung-I Yu
Jeannie Zerdes

“I can’t thank you enough for your help and the peace of mind it gave me while waiting for my results. The work you do is very important to people.”

FRIENDS (UP to $99)
Anonymous
Padmanabhan A.
Matthew & Wendy Adlai-gail
Allstate
Prabhakar Ananth
Darko Arandjelovic
Don & Danna Arnold
Elda Arsenault
Laurie & James Beckert
Kamlesh Bhagnani
Priscilla & Donal Bizer
Cathy Block & Tony Oppenheim
Christoph Bloßwey
Wirad Boonjaleangoon
Robert Britt
Bucks County Bar Association
Paolo Cecchetti
Kwok Ming Chan
Kerry Chan
Chun C. Chang
John Chau
Alice Cheung
Mingju Chin
Rida & Robert Ching
Jim Choo

Drs. Cyndie and Bruce Maryanoff (center and right) received the 2015 Community Commitment Award from HBF Board Chairman Joel Rosen at the HBF Crystal Ball. (April 2015)
Stephen Y. Chow
Henry Chuang
William & Rita F. Clark
Robert & Ethel Cohen
Mr. & Mrs. Robert S. Cohoon
Michael Conaboy
Fergal Conefrey
Michael Crowe
Raymond D’Auria
Angelo DeMeo
David Dicaprio
Mr. & Mrs. Daniel DiMaria
Dhansophoeuy Din
Vincent Do
Mary Cushing Doherty
Mr. & Mrs. Paul Dominguez
Vicki Dunn
Frederick Tobias Duque
ECHO of Northrop Grumman
E. Priya Eddy
Asmar Eyvazova
Susan L. Felker
Rosa Ferrari
Daniel Findley
Edward W. Fischer
Michelle Gerber
Clifford Goldman
John Goode
Inge Green
William Green
James Z. Guo
Cam Ha
J.C. Hamilton
Glenn Hammond
Hiroko Hatanaka
Hunt Hawkins & Elaine Smith
Betty Henderson
R.K. Hill
Mr. & Mrs. Richard Holmes
Kenny Hon
Xiaoling Hong
Aaron Hou
Steven & Jo Ann Hurley
Ron & Wendy Jawley
Susan Jeakle & Richard Paul
Vivian Jiang
Karen Jobu
Momodou Jobe
Suzanne Kahn
Ramesh Kakarla
Jenny Kimbel
Alison Kingsley
Richard & Jessica Koehler
Darlene & Craig Kuempel
Christine Kuikka & John D. Roberts
Archie Kwan
Bet Lai
Anne M. Lamontagne
Edward Lau
Mary K. Law
Chengchun Lee
John Lee
Paul Lee
Alison Lepard
Michelle T. Levesque
Ari Lumbantobing
Arron Luo
Rosie Ly
Earl Malvar
Hennessey Mariaeuria
Marijanioy Rehab Hospital
Mrs. Gerard A. Marini
Mr. & Mrs. Jim McGowan
Jacquelin Medina
Reggio A. & Neema Chong Michaud
Richard & Susan Miles
John & Wendy Miller
Sharon Lee Miskoefski
Arthur & Edit Mock
Kristofer M. Morad
Tulin & Goktug Morcol
Mr. & Mrs. Osamu Mori
Jamiu Moshood
Arunkumar Mouroujappane
Richard W. Moyer
Raju & Narasimha Nagaiah
Gorden Ndamukong
Christine Ngo
Mr. & Mrs. John P. Oldani
Michael & Maryellen Ovitt
Shoshana Pansells
John E. Perez
Evrim Feyyaz Persemsb
Aldersen Picar
Daniel T. Pratschner
Marlo President
Dmitry Prokopets
Polly M. Ranson
Jeanie Rice
Wendy Richmond
Eric Ristad & Kellan Peck
Charles & Lorie Roth
James & Kathleen Ryan
Vikram Saraf
Gary & Lauren Seem
Myong Shin
Rita S. Shiue
Mr. & Mrs. David M. Short
Vicki Shieir-Dunn
Ping Shyr
Donald G. Siering Jr.
Michael Smith
Priscilla Smith
Bo Song
Chung Song
Denise L. Stern
Michelle Sweeney
Erin Tamburri
Tad & Lori Troilo
Harry C.G. Tse
Donna M. Vidra
J. Wang
Valerie Walker
Vanessa Wenzell
Robert & Elizabeth White
Roy H. & Yueh-Au Williams
Robert & Julie Wischusen
Stephanie Woo
Jay Wrobel
Zhiang Wu
Feng Xu
Huan Xu
Mr. & Mrs. Jay Zinger
Mr. & Mrs. Thomas Zipp

“I can’t begin to express how much I appreciate your efforts to assist me in this tough situation. Thank you so much for all the information you have provided me so far. Although the news is overwhelming, it is much less so with your help.”

MATCHING GIFT PROGRAMS
Amgen Foundation Matching Gift Program
Bank of America Matching Gifts
Give With Liberty Campaign
Google Matching Gifts Program
KT Foundation Matching Gift Program
Merck Partnership for Giving
Microsoft Matching Gifts Program
JP Morgan Chase Employee Giving
Prudential Foundation Matching Gifts
Silicon Valley Community Foundation
Wells Fargo Community Support Campaign

UNITED WAY GIVING PROGRAMS
AT&T United Way Employee Giving Campaign
United Way California Capital Region
United Way of Greater Philadelphia & Southern New Jersey
United Way of King County
United Way Silicon Valley
United Way of Southeastern PA

CORPORATE GRANTS AND SPONSORSHIPS
Arbutus Biopharma
Arrowhead Research
Contravir Pharmaceuticals
Fisher Scientific
Fulton Bank Premier Division
Gilead Sciences
Novira Therapeutics
Onyx Pharmaceuticals
Powell Tate
Synergy Pharmaceuticals
Teva Pharmaceuticals
Univest Corporation of PA
VGX-Inovio Pharmaceuticals
Weis Markets

FEDERAL AND STATE GRANTS
Centers for Disease Control and Prevention
National Institutes of Health
Pennsylvania Department of Health

Many thanks to our in-kind donors who are too numerous to mention.

We apologize in advance for any errors or omissions in our Donor List despite our best efforts to be as accurate as possible. Please email editor@hepb.org or call (215) 489-4900 so that we can print corrections in our next newsletter. Thank you for your understanding.
A Nobel Challenge Met

The HBF is proud to announce the successful completion of A Nobel Challenge, a special campaign that raised $3 million for the Blumberg Institute to recruit top scientific talent and accelerate the pace of research. We appreciate the Board of Directors, Vivek Ramaswamy, and the Blumberg Family for making lead gifts to the campaign.

HBF and BSBI Board of Directors celebrate meeting A Nobel Challenge and raising $3 million to recruit the finest minds in science from around the world to work on finding a cure for hepatitis B. (November 2015)

THANK YOU TO ALL OF THE GENEROUS DONORS WHO SUPPORTED OUR RESEARCH VISION TO MAKE HEPATITIS B HISTORY!

NOBEL CHALLENGE DONORS
JULY 1, 2013—DECEMBER 31, 2015

Harvey J. Alter
Anonymous
AT&T United Way Employee Giving Campaign
Joyce Atleson
Cathy Block & Tony Oppenheim
Timothy & Joan Block
Anne Blumberg & Jonathan Dorfman
Jane Blumberg & Mark Thompson
Jean L. Blumberg
Mr. & Mrs. Melvin J. Bosma
Stan & Gerri Broadbent
Carol Broschart
Alan & Patty Brownstein
Bonnie Chang & Robert Hsu
Catherine Chang
Chang Hsu Family Charitable Trust
Kathleen Choi & John J. Kim
Margie Clapper
Chari & Paul Cohen
Joe & Molli Conti
Jackie Corwell
CTC Foundation
Loren Danzis
Charles & Jean Drew
Craig & Janet Esterly
Joshua Feldstein
Manette Fine & Michael Dabrow
Anthony & Jane Ford-Hutchinson
Mr. & Mrs. George Foussianes
Daniel & Jamie Fox
Lawrence Friedman & Mary Jo Cappuccilli
Katherine M. Gillespie
Robert G. Gish
David & Jacqui Griffith
J.C. Hamilton
Hie-Won Hann
Joseph Hediger
Luan Hong
Jacob Irving Trust
Angela Jacobsen
Meigan & Mark Josephson
Kahn Charitable Foundation
Mr. & Mrs. Solomon Katz
Kim Choi Family Fund
Ivan Kuo
Patrick Y. Lam
Arthur & Nancy Laskin
James P. Laskin
Dan Lee
Donald & Martha Leedy
Thomas B. Lemann
Mr. & Mrs. Richard Levinson
Linda Lin
Maria C. H. Lin
Sylvia Lipman
W. Thomas & Linda London
W. Robert Magee & Paula Wong
Anna M. A. Masin
William Mason
Brian McMahon
Anna Meadows & Alfred Knudson
Richard W. Moyer
Edward & Claire Newman
Anna P. O’Connell
Parkside Foundation
Janet Perper
Vivek Ramaswamy
Joel D. Rosen
Na Rothschild & Michael Cooper
Kenneth & Maria Rothstein
Christopher Santana
Thomas Shenk & Lillian Chiang
George L. Sing & Nellie Chi
William & Serena Skiversky
Mr. & Mrs. Gurney P. Sloan, Jr.
Phyllis Soref
Ray Mingruey Tai
Dr. & Mrs. John M. Taylor
Bud & Priscilla Tennant
Walter Tsou
Tulchin Family Foundation
Sharon Victor & Abraham Leibson
Seanna Walter
Philip & Philippa Wharton
Catharine & Robert Williams
Paul & Janine Witte
Marjorie K. Yeh
Yu Shuan Yeh
Wayne P. Yetter
Tianlin Zhou & Amy Yang
W. Thomas London Distinguished Professorship

Part of A Nobel Challenge campaign, the W. Thomas London Distinguished Professorship is the first named “Chair” at the Blumberg Institute and was established in 2015 to honor W. Thomas London, MD, for his transformational contributions to the discovery of the hepatitis B virus and his unwavering professional commitment to HBV for the past 50 years.

Dr. London (left) presented an honorary chair to Ju-Tao Guo, MD (right), professor and director of Experimental Therapeutics at the Blumberg Institute, as the inaugural recipient of the new W. Thomas London Distinguished Professorship. (October 2015)

THANK YOU TO ALL DONORS TO THE W. THOMAS LONDON DISTINGUISHED PROFESSORSHIP.

W. Thomas London Distinguished Professorship Donors

July 1, 2014 – December 31, 2015

Harvey J. Alter
Anonymous
Joyce Atleson
Timothy & Joan Block
Cathy Block & Tony Oppenheim
Anne Blumberg & Jonathan Dorfman
Jane Blumberg & Mark Thompson
Jean L. Blumberg
Mr. & Mrs. Melvin Bosma
Stan & Gerri Broadway
Carol Brossett
Alan & Patty Brownstein
Margie Clapper
Chari & Paul Cohen
Joe & Molli Conti
Charles & Jean Drew
Craig & Janet Esterly
Manette Fine & Michael Dabrow
Anthony & Jane Ford-Hutchinson
Dan & Jamie Fox
Lawrence Friedman & Mary Jo Cappuccilli
Long-Long Gao
Kathleen M. Gillespie
Robert G. Gish
Hie-Won Hann
Jacob Irving Trust

Arthur & Nancy Laskin
James P. Laskin
Donald & Martha Leedy
Thomas B. Lemann
Mr. & Mrs. Richard Levinson
Maria C. H. Lin
Sylvia Lipman
W. Thomas & Linda London
William Mason
Brian McMahon
Anna Meadows & Alfred Knudson
Edward & Claire Newman
Anna P. O’Connell
Parkside Foundation
Janet Perp
Vivek Ramaswamy
Joel D. Rosen
Nan Rothschild & Michael Cooper
Kenneth & Maria Rothstein
Phyllis Sorof
Ray Minguey Tai
Dr. & Mrs. John M. Taylor
Bud & Priscilla Tennant
Walter Tsou
Sharon Victor & Abraham Leibson
Catharine & Robert Williams
Paul & Janine Witte
Wayne P. Yetter
Tianlan Zhou & Amy Yang

“Your team has been extremely helpful, and I can’t thank you enough for your kindness and prompt attention to our situation.”
"I have been treating hepatitis B for many years and I am thankful to you. Knowledge has been the legacy of your world, which you generously share with everyone and being a physician I always read your articles and discoveries. Well done, Hepatitis B Foundation."

**Year In Review + Financial Information**

*Combined Hepatitis B Foundation & Baruch S. Blumberg Institute*

FOR THE FISCAL YEAR ENDED JUNE 30, 2015

**Sources of Funds**

- Grants 34% ($3,938,902)
- Charitable contributions 5% ($622,011)
- Natural Products Institute 5% ($547,634)
- Management fees 2% ($180,000)
- Technology Transfer 49% ($5,607,131)
- Special events 1% ($84,507)
- Other revenue 4% ($427,617)

*(Total $11,407,802)*

**Uses of Funds**

- Research and Biotech 59% ($3,040,738)
- Outreach and Education 9% ($460,347)
- General and Administrative 19% ($988,569)
- Rent and Depreciation 10% ($497,687)
- Academic Affiliation ($11,000)
- Development 2% ($83,611)
- Other 1% ($54,199)

*(Total $5,136,151)*

---

1 Proceeds from the sale of technology and shares of stock awarded for technology development were valued at the end of the fiscal year and documented as “Technology Transfer” revenue.

*The financial information presented above does not include the activity from Hepatitis B Foundation’s 50% interest in the net assets of the Pennsylvania Biotechnology Center. At June 30, 2015, this interest was valued at, based on the equity method of accounting, approximately $3.252 million per the audited Statement of Financial Position of the Hepatitis B Foundation. The Pennsylvania Biotechnology Center was founded in 2006 in partnership with a local college.*

The financial information in this report was prepared by management and presented in condensed form from the financial statements of the Hepatitis B Foundation and the Baruch S. Blumberg Institute, audited by EisnerAmper, LLP for the year ended June 30, 2015. A copy of each financial statement is available upon request.
The Hepatitis B Foundation and its Baruch S. Blumberg Institute are the nation’s leading nonprofit research and disease advocacy organizations dedicated to finding a cure and improving the quality of life for those affected by hepatitis B worldwide. The Hepatitis B Foundation was founded in 1991, and established the Baruch S. Blumberg Institute in 2003 to fulfill its research mission.